Table 4
Open in new tab

Quality of life

All patientsWomenMenP-valuea
SF-12 physical component
 Baseline44.6 (37.7–51.4) n = 59742.2 (36.3–48.6) n = 19645.5 (39.2–52.9) n = 401<0.001
 Follow-up48.6 (42.0–54.2)n = 56445.6 (39.8–51.3) n = 19050.8 (43.2–55.0) n = 374<0.001
 Change
  Absolute, median (q1–q3)2.5 (−2.1 to 8.1)2.1 (−3.5 to 8.4)2.7 (−1.3 to 8.0)0.26
  Percentage, median (q1–q3)5.6 (−4.0 to 20) n = 5475.1 (−6.9 to 20.9) n = 1845.9 (−3.2 to 19.1) n = 363
 P-valueb<0.0010.001<0.001
SF-12 mental component
 Baseline50.3 (42.7–57.5) n = 59848.2 (40.6–55.2) n = 19751.8 (43.6–58.0) n = 401<0.001
 Follow-up54.4 (46.0–58.6) n = 56552.9 (45.2–57.5) n = 19154.9 (47.3–59.7) n = 3740.01
 Change
  Absolute, median (q1–q3)1.2 (−3.2 to 8.0)1.8 (−3.2 to 8.7)0.4 (−3.3 to 7.7)0.17
  Percentage, median (q1–q3)2.0 (−6.6 to 17.3) n = 5483.7 (−6.1 to 19.1) n = 1851.6 (−6.6 to 16.3) n = 363
 P-valueb<0.001<0.0010.002
Karnofsky scale
 Baseline90 (80–90) n = 63380 (80–90) n = 20990 (80–90) n = 4240.04
 Follow-up100 (90–100) n = 619100 (90–100) n = 207100 (90–100) n = 4120.06
 Change
  Absolute, median (q1–q3)10 (0–10)0 (0–10)10 (0–10)0.60
  Percentage, median (q1–q3)11.1 (0.0–12.5)n = 6190 (0–12.5) n = 20711.1 (0.0–12–5) n = 412
 P-valueb<0.001<0.001<0.001
EQ-5D score
 Baseline0.80 (0.69–1.00) n = 5980.76 (0.69–0.88) n = 1980.80 (0.73–1.00) n = 400<0.001
 Follow-up0.85 (0.73–1.00) n = 5650.80 (0.69–1.00) n = 1880.85 (0.76–1.00) n = 377<0.001
 Change
  Absolute, median (q1–q3)0.00 (−0.04 to 0.14)0.00 (−0.07 to 0.12)0.00 (0.00 to 0.15)0.09
  Percentage, median (q1–q3)(−5.0 to 17.6) n = 5470.0 (−11.7 to 17.3) n = 1830.0 (0.0 to 17.6) n = 364
 P-valueb<0.0010.27<0.001
All patientsWomenMenP-valuea
SF-12 physical component
 Baseline44.6 (37.7–51.4) n = 59742.2 (36.3–48.6) n = 19645.5 (39.2–52.9) n = 401<0.001
 Follow-up48.6 (42.0–54.2)n = 56445.6 (39.8–51.3) n = 19050.8 (43.2–55.0) n = 374<0.001
 Change
  Absolute, median (q1–q3)2.5 (−2.1 to 8.1)2.1 (−3.5 to 8.4)2.7 (−1.3 to 8.0)0.26
  Percentage, median (q1–q3)5.6 (−4.0 to 20) n = 5475.1 (−6.9 to 20.9) n = 1845.9 (−3.2 to 19.1) n = 363
 P-valueb<0.0010.001<0.001
SF-12 mental component
 Baseline50.3 (42.7–57.5) n = 59848.2 (40.6–55.2) n = 19751.8 (43.6–58.0) n = 401<0.001
 Follow-up54.4 (46.0–58.6) n = 56552.9 (45.2–57.5) n = 19154.9 (47.3–59.7) n = 3740.01
 Change
  Absolute, median (q1–q3)1.2 (−3.2 to 8.0)1.8 (−3.2 to 8.7)0.4 (−3.3 to 7.7)0.17
  Percentage, median (q1–q3)2.0 (−6.6 to 17.3) n = 5483.7 (−6.1 to 19.1) n = 1851.6 (−6.6 to 16.3) n = 363
 P-valueb<0.001<0.0010.002
Karnofsky scale
 Baseline90 (80–90) n = 63380 (80–90) n = 20990 (80–90) n = 4240.04
 Follow-up100 (90–100) n = 619100 (90–100) n = 207100 (90–100) n = 4120.06
 Change
  Absolute, median (q1–q3)10 (0–10)0 (0–10)10 (0–10)0.60
  Percentage, median (q1–q3)11.1 (0.0–12.5)n = 6190 (0–12.5) n = 20711.1 (0.0–12–5) n = 412
 P-valueb<0.001<0.001<0.001
EQ-5D score
 Baseline0.80 (0.69–1.00) n = 5980.76 (0.69–0.88) n = 1980.80 (0.73–1.00) n = 400<0.001
 Follow-up0.85 (0.73–1.00) n = 5650.80 (0.69–1.00) n = 1880.85 (0.76–1.00) n = 377<0.001
 Change
  Absolute, median (q1–q3)0.00 (−0.04 to 0.14)0.00 (−0.07 to 0.12)0.00 (0.00 to 0.15)0.09
  Percentage, median (q1–q3)(−5.0 to 17.6) n = 5470.0 (−11.7 to 17.3) n = 1830.0 (0.0 to 17.6) n = 364
 P-valueb<0.0010.27<0.001

All values are depicted as median (q1–q3). In all cells, the number (n) of patients with available data is shown.

a

P-value women vs. men.

b

P-value between baseline and end of follow-up measurements.

EQ-5D, Euro-QoL 5-Dimensional questionnaire; SF-12, 12-item Short Form Health Survey.

Table 4
Open in new tab

Quality of life

All patientsWomenMenP-valuea
SF-12 physical component
 Baseline44.6 (37.7–51.4) n = 59742.2 (36.3–48.6) n = 19645.5 (39.2–52.9) n = 401<0.001
 Follow-up48.6 (42.0–54.2)n = 56445.6 (39.8–51.3) n = 19050.8 (43.2–55.0) n = 374<0.001
 Change
  Absolute, median (q1–q3)2.5 (−2.1 to 8.1)2.1 (−3.5 to 8.4)2.7 (−1.3 to 8.0)0.26
  Percentage, median (q1–q3)5.6 (−4.0 to 20) n = 5475.1 (−6.9 to 20.9) n = 1845.9 (−3.2 to 19.1) n = 363
 P-valueb<0.0010.001<0.001
SF-12 mental component
 Baseline50.3 (42.7–57.5) n = 59848.2 (40.6–55.2) n = 19751.8 (43.6–58.0) n = 401<0.001
 Follow-up54.4 (46.0–58.6) n = 56552.9 (45.2–57.5) n = 19154.9 (47.3–59.7) n = 3740.01
 Change
  Absolute, median (q1–q3)1.2 (−3.2 to 8.0)1.8 (−3.2 to 8.7)0.4 (−3.3 to 7.7)0.17
  Percentage, median (q1–q3)2.0 (−6.6 to 17.3) n = 5483.7 (−6.1 to 19.1) n = 1851.6 (−6.6 to 16.3) n = 363
 P-valueb<0.001<0.0010.002
Karnofsky scale
 Baseline90 (80–90) n = 63380 (80–90) n = 20990 (80–90) n = 4240.04
 Follow-up100 (90–100) n = 619100 (90–100) n = 207100 (90–100) n = 4120.06
 Change
  Absolute, median (q1–q3)10 (0–10)0 (0–10)10 (0–10)0.60
  Percentage, median (q1–q3)11.1 (0.0–12.5)n = 6190 (0–12.5) n = 20711.1 (0.0–12–5) n = 412
 P-valueb<0.001<0.001<0.001
EQ-5D score
 Baseline0.80 (0.69–1.00) n = 5980.76 (0.69–0.88) n = 1980.80 (0.73–1.00) n = 400<0.001
 Follow-up0.85 (0.73–1.00) n = 5650.80 (0.69–1.00) n = 1880.85 (0.76–1.00) n = 377<0.001
 Change
  Absolute, median (q1–q3)0.00 (−0.04 to 0.14)0.00 (−0.07 to 0.12)0.00 (0.00 to 0.15)0.09
  Percentage, median (q1–q3)(−5.0 to 17.6) n = 5470.0 (−11.7 to 17.3) n = 1830.0 (0.0 to 17.6) n = 364
 P-valueb<0.0010.27<0.001
All patientsWomenMenP-valuea
SF-12 physical component
 Baseline44.6 (37.7–51.4) n = 59742.2 (36.3–48.6) n = 19645.5 (39.2–52.9) n = 401<0.001
 Follow-up48.6 (42.0–54.2)n = 56445.6 (39.8–51.3) n = 19050.8 (43.2–55.0) n = 374<0.001
 Change
  Absolute, median (q1–q3)2.5 (−2.1 to 8.1)2.1 (−3.5 to 8.4)2.7 (−1.3 to 8.0)0.26
  Percentage, median (q1–q3)5.6 (−4.0 to 20) n = 5475.1 (−6.9 to 20.9) n = 1845.9 (−3.2 to 19.1) n = 363
 P-valueb<0.0010.001<0.001
SF-12 mental component
 Baseline50.3 (42.7–57.5) n = 59848.2 (40.6–55.2) n = 19751.8 (43.6–58.0) n = 401<0.001
 Follow-up54.4 (46.0–58.6) n = 56552.9 (45.2–57.5) n = 19154.9 (47.3–59.7) n = 3740.01
 Change
  Absolute, median (q1–q3)1.2 (−3.2 to 8.0)1.8 (−3.2 to 8.7)0.4 (−3.3 to 7.7)0.17
  Percentage, median (q1–q3)2.0 (−6.6 to 17.3) n = 5483.7 (−6.1 to 19.1) n = 1851.6 (−6.6 to 16.3) n = 363
 P-valueb<0.001<0.0010.002
Karnofsky scale
 Baseline90 (80–90) n = 63380 (80–90) n = 20990 (80–90) n = 4240.04
 Follow-up100 (90–100) n = 619100 (90–100) n = 207100 (90–100) n = 4120.06
 Change
  Absolute, median (q1–q3)10 (0–10)0 (0–10)10 (0–10)0.60
  Percentage, median (q1–q3)11.1 (0.0–12.5)n = 6190 (0–12.5) n = 20711.1 (0.0–12–5) n = 412
 P-valueb<0.001<0.001<0.001
EQ-5D score
 Baseline0.80 (0.69–1.00) n = 5980.76 (0.69–0.88) n = 1980.80 (0.73–1.00) n = 400<0.001
 Follow-up0.85 (0.73–1.00) n = 5650.80 (0.69–1.00) n = 1880.85 (0.76–1.00) n = 377<0.001
 Change
  Absolute, median (q1–q3)0.00 (−0.04 to 0.14)0.00 (−0.07 to 0.12)0.00 (0.00 to 0.15)0.09
  Percentage, median (q1–q3)(−5.0 to 17.6) n = 5470.0 (−11.7 to 17.3) n = 1830.0 (0.0 to 17.6) n = 364
 P-valueb<0.0010.27<0.001

All values are depicted as median (q1–q3). In all cells, the number (n) of patients with available data is shown.

a

P-value women vs. men.

b

P-value between baseline and end of follow-up measurements.

EQ-5D, Euro-QoL 5-Dimensional questionnaire; SF-12, 12-item Short Form Health Survey.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close